Nicholas Investment Partners LP Has $2.53 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Nicholas Investment Partners LP trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 23.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,147 shares of the biopharmaceutical company's stock after selling 25,559 shares during the period. Nicholas Investment Partners LP owned 0.05% of TG Therapeutics worth $2,533,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of TG Therapeutics by 3.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 92,683 shares of the biopharmaceutical company's stock worth $2,808,000 after buying an additional 2,890 shares during the last quarter. Integral Health Asset Management LLC acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $4,515,000. Deutsche Bank AG grew its holdings in TG Therapeutics by 40.4% during the fourth quarter. Deutsche Bank AG now owns 147,020 shares of the biopharmaceutical company's stock valued at $4,425,000 after purchasing an additional 42,272 shares during the period. Cornerstone Select Advisors LLC acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $1,904,000. Finally, Brevan Howard Capital Management LP acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $453,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Stock Up 2.3%

Shares of NASDAQ:TGTX traded up $0.77 during midday trading on Friday, reaching $34.36. 1,924,148 shares of the company were exchanged, compared to its average volume of 3,004,449. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a fifty day simple moving average of $38.59 and a two-hundred day simple moving average of $33.90. The firm has a market cap of $5.46 billion, a PE ratio of -343.57 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the previous year, the business earned ($0.07) earnings per share. The company's revenue was up 90.4% on a year-over-year basis. As a group, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TGTX shares. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.